ESR1 and breast cancer: Unlike other breast cancer subtypes, such as triple‐negative and HER2‐enriched breast cancer, which commonly relapse within the first few years of follow‐up, ER+/ERBB2‐ invasive breast cancer often presents with a late recurrence, manifesting 5–10 years or longer after primary treatment.3